PRULady

PRULady is Prudential Indonesia’s gender-specific critical-illness policy. It is narrower than a unisex CI product by design — only women can be the insured, and the covered Kondisi Kritis (critical condition) is limited to breast cancer. In exchange for that narrower risk pool, the policy stacks an unusually rich set of benefits: Early-stage CI 25% UP (Uang Pertanggungan / sum assured), End-stage CI 100% UP, Surgery (Bedah) 20%, Reconstructive Surgery (Bedah Rekonstruktif) 20%, Molecular Gene Profile test rider 5%, and Mental Health Consultation Support 0.1% per visit. Total cumulative claim ceiling is 140% UP (funeral benefit Rp 25M sits on top). PRULady Save offers a 5% premium discount each year the insured passes a defined health check. Plan Basic ends at age 85 with no death-benefit lump sum; Plan Plus runs the death benefit to age 90.

In one line: if a woman is specifically worried about breast cancer and is willing to do an annual medical check, PRULady is the most condition-targeted product in the market.

---

The RIPLAY publishes three illustrative scenarios. The cleanest one for agent conversations is Scenario 2 — a 46-year-old female, Rp 500M UP, 10-year PPT (premium payment term), Plan Basic, who is diagnosed with End-stage CI and proceeds through surgery and reconstruction. Decoded:

Sub-cap to flag explicitly: the Rp 2.5B Early-stage CI ceiling, the Rp 500M Surgery ceiling, the Rp 500M Reconstructive ceiling, and the Rp 100M Gene Profile ceiling are absolute caps measured across ALL PRULady policies a single Tertanggung holds, not per policy. A customer with two PRULady policies cannot stack these benefits beyond the cap.

Premium reference points (from RIPLAY):

The agent narrative anchor: PRULady is not cheap relative to a unisex term-CI rider, but the manfaat density is high if the covered event happens. If breast cancer is the specific worry — particularly with family history — the math works because the cover is purpose-built.

---

Sweet Spot — Lead with PRULady (competitor framing)

• Women age 28-45 with a family history of breast cancer or general female-side oncology

• Working professionals or business owners, household income Rp 15M+/month, financially comfortable enough to add a layered policy

• Health-conscious prospects willing to undergo an annual medical check-up to lock in the PRULady Save discount path

• Already owns basic health/medical insurance (BPJS Kesehatan plus a private hospital card or employer-provided medical) — PRULady is a layered CI cover, not a replacement for hospitalization

• Wants female-specific cover rather than a unisex CI bucket — common with prospects who have done their own research and want the condition-targeted product

• Married women with dependents where breast-cancer treatment cost would damage the family’s financial trajectory

Borderline Fit

• Women age 46-55 — premium loads heavily and 15-year PPT cap is age 50; 10-year PPT cap is age 55. Workable but case-size and structure choices narrow.

• Single women without dependents — possible if framed around the customer’s own treatment-cost cushion and dignity in recovery, not legacy

• Women who already own a unisex CI policy (Allianz CI Premier, AIA Vital Care, Manulife CI products) — probe the gap; PRULady should layer breast-specific cover, not duplicate

• Customers with no family history but high health anxiety — the product fits but the agent must be careful not to inflate the risk story; OJK conduct rules apply

Do Not Pitch

• Men — N/A, female-only insured

• Customers without basic health insurance — sell hospital cash or a medical card first; CI lump-sum is the wrong priority

• Mass-market budget-constrained prospects — Rp 300M minimum UP and Rp 3.3M annual minimum premium price out the lower mass market

• Women age 56+ — outside the entry-age window for any PPT; not eligible

• Customers signaling lapse risk (income volatility, recent job loss, business stress) — the surrender value table starts at 0% Year 1 and the lapse penalty is unforgiving in early years

• Customers who want investment upside — this is pure protection, not a savings vehicle

---

Rule of thumb (trigger phrases in Bahasa): if the customer’s first sentence contains “nenek/ibu/tante kena kanker” (grandmother/mother/aunt had cancer), “kanker payudara” (breast cancer), “deteksi dini” (early detection), or “perempuan-only” / “khusus wanita” (women-only), PRULady is in the conversation. If she says “semua penyakit kritis” (all critical illnesses), “yang penting murah” (just want it cheap), or “ada investasinya” (with an investment component), it isn’t — switch products.

---

The Indonesian critical-illness category is structurally heterogeneous (26 catalogued products, 23 with PDFs on disk, <60% on every quantitative metric per category-benchmarks.json dated 2026-05-08). The gender-specific sub-category has only 2-3 close peers domestically. The benchmarking below is qualitative.

Confidence note: structural-dimension claims are high-confidence (drawn directly from RIPLAY and brochure). Competitor-comparison claims are analyst assessment from category knowledge, not directly benchmarked against parsed competitor RIPLAYs (refresh when critical-illness category PDF coverage exceeds 60% on quantitative metrics).

---

These are scripts for Legacy Income agents who encounter a prospect already owning, already considering, or already pitched PRULady. The frame is competitive intelligence, not Prudential advocacy.

Opening — establish the right frame

“PRULady is a well-designed product for one specific risk — breast cancer. The question I’d help you answer is whether one risk is the right way to plan, or whether your protection should cover a wider range of what could actually happen to your health over the next 30 years.”

“PRULady itu produk yang bagus untuk satu risiko spesifik — kanker payudara. Pertanyaan yang ingin saya bantu jawab adalah apakah satu risiko itu cara yang tepat untuk planning, atau apakah proteksi Anda sebaiknya cover lebih luas — apa pun yang bisa terjadi pada kesehatan Anda dalam 30 tahun ke depan.”

The structural value prop — surface the trade-off

“PRULady will pay you a lot if you get breast cancer. Up to 140% of your sum assured — that’s surgery, reconstruction, gene-profile testing, mental health support, all included. But every rupiah is locked to that one condition. If you get cervical cancer, ovarian cancer, a heart attack, or a stroke — PRULady pays zero. The product I work with covers 50-plus critical conditions at a comparable premium. Different design philosophy.”

“PRULady akan bayar besar kalau Anda kena kanker payudara. Sampai 140% dari Uang Pertanggungan — bedah, rekonstruksi, tes gen, dukungan kesehatan mental, semua include. Tapi setiap rupiah-nya terkunci di satu kondisi itu. Kalau kena kanker serviks, kanker ovarium, serangan jantung, atau stroke — PRULady bayar nol. Produk yang saya pegang cover 50-an kondisi kritis dengan premi yang sebanding. Filosofi desainnya beda.”

The PRULady Save pitch — premium discount for being healthy

“There is one feature in PRULady worth understanding clearly — PRULady Save. You get 5% off next year’s premium if you do an annual medical check-up that meets Prudential’s criteria. Two things to know: first, it’s only 5% — modest, not transformational. Second, you have to do the medical check at a Prudential-designated location every year, and you have to pass the criteria. If you skip a year or fail the criteria, the discount disappears for that year. For someone disciplined about annual check-ups it’s a small bonus. For someone who’d struggle to keep up, it’s not a real factor in the decision.”

“Ada satu fitur di PRULady yang perlu dipahami baik-baik — PRULady Save. Anda dapat potongan 5% premi tahun depan kalau Anda melakukan medical check-up tahunan yang memenuhi kriteria Prudential. Dua hal yang perlu diketahui: pertama, hanya 5% — modest, bukan transformatif. Kedua, Anda harus medical check di tempat yang ditentukan Prudential setiap tahun, dan harus lulus kriteria. Kalau skip satu tahun atau gagal kriteria, diskonnya hilang untuk tahun itu. Untuk yang disiplin medical check tahunan, ini bonus kecil. Untuk yang akan kesulitan rutin, ini bukan faktor riil dalam keputusan.”

The close — move to action

“Here’s what I’d suggest. If you’re worried specifically about breast cancer because of family history, PRULady is a legitimate product and you should keep it on the table. But before you commit, let me show you a side-by-side: PRULady at your projected premium versus a broader CI product at the same premium. Same money, different protection footprint. You decide which footprint matches your real concern. Can we book 30 minutes this week?”

“Saran saya begini. Kalau Anda memang khawatir spesifik soal kanker payudara karena ada riwayat keluarga, PRULady itu produk yang legitimate dan boleh tetap dipertimbangkan. Tapi sebelum commit, izinkan saya tunjukkan perbandingan: PRULady di premi yang Anda proyeksikan vs produk CI yang lebih luas di premi yang sama. Uang yang sama, jejak proteksi yang beda. Anda yang putuskan jejak mana yang cocok dengan kekhawatiran Anda yang sebenarnya. Bisa kita atur 30 menit minggu ini?”

—

These are the objections Legacy Income agents will hear when prospects already own or are considering PRULady.

1. “I already have a regular CI policy — why duplicate?”

Customer “Saya sudah punya asuransi CI biasa, kenapa harus duplikasi?”

Don't say “You should buy both.” — sounds like you’re stacking commissions.

Don't say “Anda harus beli dua-duanya.”

Do say “Not duplication — layering. Your existing unisex CI pays on a broad list including breast cancer, but typically as a single lump-sum trigger. PRULady’s value-add IF you keep it is the post-claim surgery and reconstruction layer that most unisex products don’t bundle. The right question is whether that incremental cover is worth the incremental premium. Let’s run the numbers — I’ll show you what your existing policy actually pays on a breast-cancer claim, and we’ll see if PRULady adds enough on top to justify the cost.”

Do say “Bukan duplikasi — layering. CI unisex yang sudah Anda punya bayar untuk list yang luas termasuk kanker payudara, tapi biasanya sekali bayar lump-sum saja. Nilai tambah PRULady kalau dipertahankan ada di lapisan bedah dan rekonstruksi pasca-klaim yang kebanyakan produk unisex tidak bundle. Pertanyaan yang tepat adalah apakah cover tambahan itu sepadan dengan premi tambahan. Mari hitung — saya tunjukkan polis Anda saat ini bayar berapa untuk klaim kanker payudara, lalu kita lihat apakah PRULady menambah cukup di atasnya untuk justify biayanya.”

—

2. “It’s expensive — I’m paying high premium for something that might never happen.”

Customer “Mahal — premi tinggi padahal saya belum tentu kena kanker.”

Don't say “Cancer is common, you should be scared.” — fear-based selling, OJK risk.

Don't say “Kanker itu umum, harus takut.”

Do say “That’s the right question to ask about any protection product — what’s the cost relative to the probability and severity. Let me reframe it: breast cancer is the leading cancer in Indonesian women, and the treatment cost from diagnosis to recovery typically runs Rp 200-500M out of pocket once you factor in surgery, chemo, and reconstruction. PRULady’s premium is the cost of converting that unknown bill into a known annual number. The honest answer is — if your family history is clean and you have strong existing health cover, the math might not work for you. If your family history isn’t clean, the math works decisively. Let’s look at your situation specifically.”

Do say “Itu pertanyaan yang tepat untuk setiap produk proteksi — biaya dibanding probabilitas dan severity. Saya re-frame: kanker payudara adalah kanker tertinggi pada perempuan Indonesia, dan biaya treatment dari diagnosa sampai recovery biasanya Rp 200-500 juta out-of-pocket setelah hitung operasi, kemo, dan rekonstruksi. Premi PRULady adalah biaya untuk convert tagihan tak terduga itu jadi angka tahunan yang pasti. Jujur — kalau riwayat keluarga Anda bersih dan health cover existing Anda kuat, hitungan-nya mungkin tidak masuk. Kalau riwayat keluarga tidak bersih, hitungan-nya jelas masuk. Mari kita lihat situasi Anda spesifik.”

—

3. “If I don’t get cancer, the premium is wasted.”

Customer “Kalau saya nggak kena kanker, premi hilang sia-sia kan?”

Don't say “It’s not wasted, it’s protection.” — too generic, customer hears it as sales talk.

Don't say “Tidak hilang kok, itu proteksi.”

Do say “By design, term-CI products like PRULady are pure protection — they don’t return premium at the end. That’s also why the premium is much lower than an investment-linked or endowment product would be for the same coverage. The honest framing is: PRULady is insurance, not savings. If you want a product that returns money to you if no claim happens, that’s a different category — endowment or unit-linked — and the premium will be significantly higher. Different problems, different products. Want me to show you what an endowment alternative would cost for similar protection?”

Do say “Memang by design, produk term-CI seperti PRULady itu proteksi murni — tidak ada pengembalian premi di akhir. Itu juga sebabnya preminya jauh lebih rendah dibanding produk unit-linked atau endowment untuk coverage yang sama. Framing yang jujur: PRULady itu asuransi, bukan tabungan. Kalau Anda mau produk yang mengembalikan uang kalau tidak ada klaim, itu kategori berbeda — endowment atau unit-linked — dan preminya jauh lebih tinggi. Masalah beda, produk beda. Mau saya tunjukkan opsi endowment untuk proteksi serupa, biar Anda compare?”

—

4. “I’d rather invest in mutual funds — I can use the returns for treatment if I ever get cancer.”

Customer “Saya lebih percaya investasi reksadana — bisa untuk biaya kalau kena kanker.”

Don't say “Mutual funds are too risky.” — dismissive and you probably want her diversified anyway.

Don't say “Reksadana terlalu berisiko.”

Do say “Smart approach in principle — but timing is the issue. If breast cancer is diagnosed in Year 3 of your investing journey, you might have Rp 50M built up. Treatment cost is Rp 200-500M. The gap is what insurance covers from day one. Insurance and investing solve different problems. The investing is for the long-term wealth-building; the CI cover is for the early-years gap when your invested capital hasn’t accumulated yet. Both belong in a complete plan — neither replaces the other. What I’d push back on is the assumption that mutual funds are an alternative to CI cover. They aren’t — they’re a complement.”

Do say “Pendekatan yang smart secara prinsip — masalahnya di timing. Kalau kanker payudara terdiagnosa di tahun ke-3 perjalanan investasi Anda, mungkin baru terkumpul Rp 50 juta. Biaya treatment Rp 200-500 juta. Gap itu yang ditutup asuransi dari hari pertama. Asuransi dan investasi memecahkan masalah yang beda. Investasi untuk wealth-building jangka panjang; cover CI untuk gap tahun-tahun awal saat modal investasi belum terkumpul. Dua-duanya bagian dari plan yang lengkap — tidak saling mengganti. Yang saya push back adalah asumsi reksadana itu alternatif untuk CI cover. Bukan — itu komplemen.”

—

5. “Plan Basic vs Plan Plus — I’m confused, which is more efficient?”

Customer “Plan Basic vs Plan Plus — saya bingung, lebih hemat yang mana?”

Don't say “Just pick Plan Basic, it’s cheaper.” — wrong framing if she has dependents.

Don't say “Plan Basic saja, lebih murah.”

Do say “The structural difference: Plan Basic pays only a Rp 25M funeral benefit on death. Plan Plus pays up to 100% of your sum assured on death, on top of the funeral benefit. The decision rule is simple: if you have dependents who would suffer financially if you died, Plan Plus is the right answer because the death benefit is meaningful. If you have no dependents — single, no children, parents financially independent — Plan Basic is fine. The ‘cheaper’ question is the wrong question. The right question is ‘who else needs my insurance money if I die before age 90?’ The answer to that determines Plan Basic or Plus, not the premium difference.”

Do say “Bedanya struktural: Plan Basic hanya bayar santunan pemakaman Rp 25 juta saat meninggal. Plan Plus bayar sampai 100% Uang Pertanggungan saat meninggal, di atas santunan pemakaman. Aturan pilih-nya simpel: kalau ada tanggungan yang akan kesulitan finansial kalau Anda meninggal, Plan Plus jawabannya karena death benefit-nya signifikan. Kalau tidak ada tanggungan — single, belum punya anak, orang tua mandiri secara finansial — Plan Basic cukup. Pertanyaan ‘mana yang lebih hemat’ itu pertanyaan yang salah. Pertanyaan yang tepat adalah ‘siapa yang butuh uang asuransi saya kalau saya meninggal sebelum usia 90?’ Jawabannya menentukan Plan Basic atau Plus, bukan selisih premi-nya.”

—

These are issues most likely to trigger an OJK complaint or future churn-back. The same compliance discipline applies whether the agent is selling PRULady directly (not Legacy Income’s path) or coaching a prospect on a competitor product.

1. Aggregate sum assured cap Rp 2.5B per insured for Early-stage CI. The RIPLAY caps the Early CI manfaat at Rp 2.5B across ALL PRULady policies a single Tertanggung holds. A customer who buys two PRULady policies expecting Early CI to scale linearly will be disappointed. Surgery and Reconstructive are similarly capped at Rp 500M each in aggregate. Gene Profile capped at Rp 100M. Walk the customer through these caps explicitly if she’s considering multi-policy structuring or has high UP appetite.

2. The 140% UP cumulative ceiling explanation must be walked through clearly. The customer must understand which manfaat reduce which UP. Early-stage CI reduces the UP available at End-stage and Death (Plan Plus). End-stage CI reduces the death benefit pool further. Surgery, Reconstructive, and Gene Profile only trigger AFTER an End-stage CI claim and stack to 40% UP combined. Funeral benefit Rp 25M is the only manfaat that sits outside the 140% ceiling. Customers who think every manfaat is additive without offset will mis-understand what they bought.

3. PRULady Save discount is conditional — never pitch it as guaranteed. The 5% discount depends on the insured completing an annual medical check at a Prudential-designated location and meeting Prudential’s criteria. If the criteria are missed in any year, the discount disappears for that year. Marketing the discount as a “5% lower premium” without the conditionality is mis-selling. Document the customer’s acknowledgement of the conditionality.

4. Manfaat saling mengurangi — the cross-reduction logic is the #1 mis-selling risk on this product. Customers who hear “Early CI 25% + End CI 100% + Surgery 20% + Reconstructive 20% + Gene Profile 5% + Mental Health” and add them up to 145.1% will be disappointed when they discover the manfaat reduce each other and cap at 140%. The agent must verbally walk through one of the RIPLAY simulation scenarios (Scenario 2 is the clearest: Early CI 25% then End CI 100% then Surgery 20% then Reconstructive 20% equals up to 140%, not 165%).

5. Surgery and Reconstructive are conditional on prior End-stage CI claim. A customer who undergoes preventive mastectomy or surgery WITHOUT a prior End-stage CI claim collects nothing under Surgery/Reconstructive. The trigger sequence matters: End-stage CI must be claimed first, then Surgery/Reconstructive are payable for related procedures. Customers who think Surgery is a stand-alone benefit will complain at claim time.

6. Mental Health benefit is small — never inflate it. The Mental Health Support pays 0.1% UP per consultation (max Rp 1M each), capped at 10 outpatient visits over the entire policy term. On a Rp 500M UP that’s up to Rp 5M total — symbolic, not financially material. The benefit is real and well-designed, but pitching it as “psychiatric coverage” overstates what’s actually delivered.

7. 90-day waiting period for CI claims. During the first 90 calendar days from inception or reinstatement, no CI claim is payable. Customers who experience symptoms in the waiting period are excluded. Walk the customer through this on application — some prospects have undiagnosed concerns and a clean SPAJ that hides them creates a future repudiation risk under the 2-year contestable period.

---

---

1. Build a one-page “PRULady vs Unisex CI” comparison handout in EN + ID for Legacy Income agents. The comparison anchor is coverage breadth: 50+ CI conditions in a unisex CI policy vs 1 condition (breast cancer) in PRULady, at comparable premium. This is Legacy Income’s strongest competitive line. Have the handout sample-tested against a Prudential agent’s actual pitch deck before rollout.

2. Translate breast-cancer-specific risk education for Legacy Income’s female recruits. Female agents will pitch female prospects more credibly if they can confidently discuss breast cancer epidemiology in Indonesia (WHO/GLOBOCAN figures), treatment cost ranges (Rp 200-500M), and the role of CI lump-sums vs medical card cover. Build a 30-minute training module.

3. Note the manfaat sub-cap structure (Rp 2.5B Early CI, Rp 500M Surgery, Rp 500M Reconstruction, Rp 100M Gene Profile) as a competitive entry point for high-net-worth female prospects. A prospect with a Rp 5B+ protection appetite cannot fully deploy PRULady because the sub-caps bind. Confirm Tokio Marine and Allianz CI spec sheets do not have equivalent sub-caps (Tokio Marine CI Guard, Allianz CI Premier) before deploying the pitch. Refresh trigger: confirm with Tokio Marine and Allianz product desk within 14 days.

4. Refresh trigger: when Indonesia Life Insurance Market Intelligence project’s critical-illness category PDF coverage exceeds 60% on quantitative metrics, re-run this brief against actual benchmarks. Until then, the qualitative comparison and RIPLAY-direct citations stand. Also refresh if Prudential publishes a PRULady product variant (PRULady 2, PRULady Plus, etc.) — the brand has a pattern of versioning gender-specific lines.

5. Pair-sell guidance: if the customer owns PRULady, what to layer on top. The complementary product is a unisex CI rider on a Tokio Marine or Allianz base policy that covers the 50+ conditions PRULady doesn’t. The pitch frame is “your breast-cancer cover is sorted, let’s close the cervical / ovarian / cardiovascular / stroke gap.” Build a 1-page pair-sell script and deploy through Legacy Income’s WhatsApp distribution within 21 days.

---